Aliases & Classifications for Fainting

MalaCards integrated aliases for Fainting:

Name: Fainting 54 43

Summaries for Fainting

MedlinePlus : 43 Fainting is a temporary loss of consciousness. If you're about to faint, you'll feel dizzy, lightheaded, or nauseous. Your field of vision may "white out" or "black out." Your skin may be cold and clammy. You lose muscle control at the same time, and may fall down. Fainting usually happens when your blood pressure drops suddenly, causing a decrease in blood flow to your brain. It is more common in older people. Some causes of fainting include Heat or dehydration Emotional distress Standing up too quickly Certain medicines Drop in blood sugar Heart problems When someone faints, make sure that the airway is clear and check for breathing. The person should stay lying down for 10-15 minutes. Most people recover completely. Fainting is usually nothing to worry about, but it can sometimes be a sign of a serious problem. If you faint, it's important to see your health care provider and find out why it happened.

MalaCards based summary : Fainting is related to atrial fibrillation and myocardial infarction. An important gene associated with Fainting is KCNH2 (Potassium Voltage-Gated Channel Subfamily H Member 2), and among its related pathways/superpathways are Formation of Fibrin Clot (Clotting Cascade) and Complement and coagulation cascades. The drugs Midodrine and Petrolatum have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and heart.

Wikipedia : 76 Syncope, also known as fainting, is a loss of consciousness and muscle strength characterized by a fast... more...

Related Diseases for Fainting

Diseases related to Fainting via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 105)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 31.2 KCNH2 VWF
2 myocardial infarction 30.6 CHKB F8 VWF
3 syncope 11.5
4 long qt syndrome 11.2
5 postural orthostatic tachycardia syndrome 11.2
6 jervell and lange-nielsen syndrome 1 11.1
7 chronic orthostatic intolerance 11.1
8 myotonia congenita, autosomal recessive 11.1
9 aortic valve disease 2 11.1
10 myotonia congenita 11.1
11 long qt syndrome 1 11.0
12 cardiomyopathy, familial hypertrophic, 1 11.0
13 osteogenesis imperfecta, type xiii 11.0
14 brugada syndrome 11.0
15 familial atrial fibrillation 11.0
16 ectopic pregnancy 11.0
17 catecholaminergic polymorphic ventricular tachycardia 11.0
18 vibratory urticaria 10.8
19 multiple system atrophy 1 10.8
20 pulmonary hypertension, primary, 1 10.8
21 hypoadrenocorticism, familial 10.8
22 peters-plus syndrome 10.8
23 brugada syndrome 1 10.8
24 long qt syndrome 3 10.8
25 syncope, familial vasovagal 10.8
26 hyperinsulinemic hypoglycemia, familial, 7 10.8
27 brugada syndrome 2 10.8
28 brugada syndrome 3 10.8
29 brugada syndrome 4 10.8
30 brugada syndrome 5 10.8
31 brugada syndrome 6 10.8
32 brugada syndrome 7 10.8
33 brugada syndrome 8 10.8
34 long qt syndrome 2 10.8
35 brugada syndrome 9 10.8
36 dilated cardiomyopathy 10.8
37 arrhythmogenic right ventricular cardiomyopathy 10.8
38 patent foramen ovale 10.8
39 ovarian cyst 10.8
40 phobic disorder 10.8
41 amyloidosis 10.8
42 hypertrophic cardiomyopathy 10.8
43 autoimmune autonomic ganglionopathy 10.8
44 familial progressive cardiac conduction defect 10.8
45 hereditary alpha tryptasemia syndrome 10.8
46 multiple system atrophy with orthostatic hypotension 10.8
47 epilepsy 10.1
48 anxiety 10.0
49 malaria 10.0
50 pemphigus foliaceus 10.0

Graphical network of the top 20 diseases related to Fainting:



Diseases related to Fainting

Symptoms & Phenotypes for Fainting

Drugs & Therapeutics for Fainting

Drugs for Fainting (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 543)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midodrine Approved Phase 4,Not Applicable 133163-28-7, 42794-76-3 4195
2
Petrolatum Approved, Investigational Phase 4,Phase 2 8009-03-8
3
Titanium dioxide Approved Phase 4 13463-67-7
4
Ethanol Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
5
mometasone furoate Approved, Vet_approved Phase 4 83919-23-7
6
Amiodarone Approved, Investigational Phase 4,Phase 3 1951-25-3 2157
7
Ranolazine Approved, Investigational Phase 4,Phase 2 142387-99-3, 95635-55-5 56959
8
Propranolol Approved, Investigational Phase 4,Phase 2,Not Applicable 525-66-6 4946
9
Carvedilol Approved, Investigational Phase 4,Phase 1,Phase 2 72956-09-3 2585
10
Amlodipine Approved Phase 4,Phase 2 88150-42-9 2162
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 58-93-5 3639
12
leucovorin Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-05-9 6006 143
13
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
14
Enalaprilat Approved Phase 4 76420-72-9 6917719
15
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
16
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 185243-69-0
17
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
18
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
19
Losartan Approved Phase 4 114798-26-4 3961
20
Glyburide Approved Phase 4,Phase 3 10238-21-8 3488
21
Gliclazide Approved Phase 4,Phase 3 21187-98-4 3475
22
Glimepiride Approved Phase 4,Phase 3 93479-97-1 3476
23
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
24
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 5311051 32798
25
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
26
Testosterone Approved, Investigational Phase 4 58-22-0 6013
27
Testosterone enanthate Approved Phase 4 315-37-7 9416
28
Methyltestosterone Approved Phase 4 58-18-4 6010
29
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
30
Donepezil Approved Phase 4,Phase 2 120014-06-4 3152
31
Epoprostenol Approved Phase 4,Phase 3,Phase 2 61849-14-7, 35121-78-9 5280427 5282411
32
Treprostinil Approved, Investigational Phase 4,Phase 3,Phase 2 81846-19-7 54786 6918140
33
Brinzolamide Approved Phase 4 138890-62-7 68844
34
Timolol Approved Phase 4,Phase 2,Not Applicable 26839-75-8 33624 5478
35
Acitretin Approved Phase 4 55079-83-9 5284513 6437841
36
Adalimumab Approved Phase 4,Phase 3 331731-18-1 16219006
37
Ketoconazole Approved, Investigational Phase 4 65277-42-1 3823 47576
38
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
39
Macitentan Approved Phase 4,Phase 3,Phase 2 441798-33-0
40
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
41
Sertraline Approved Phase 4 79617-96-2 68617
42
Tavaborole Approved, Investigational Phase 4 174671-46-6
43
Clindamycin Approved, Vet_approved Phase 4,Phase 3 18323-44-9 29029
44
Benzoyl peroxide Approved Phase 4,Phase 3 94-36-0 7187
45
Adapalene Approved Phase 4 106685-40-9 60164
46
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
47
Droxidopa Approved, Investigational Phase 4,Phase 3,Phase 2 23651-95-8 443940
48
Bisoprolol Approved Phase 4,Phase 3,Phase 2 66722-44-9 2405
49
Pimecrolimus Approved, Investigational Phase 4,Phase 3 137071-32-0 6447131 17753757
50
Atenolol Approved Phase 4 29122-68-7 2249

Interventional clinical trials:

(show top 50) (show all 585)
# Name Status NCT ID Phase Drugs
1 Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study) Unknown status NCT01621464 Phase 4
2 Assessment of Midodrine in the Prevention of Vasovagal Syncope: The Prevention of Syncope Trial IV Unknown status NCT01456481 Phase 4 midodrine hydrochloride;matching placebo
3 Syncope: Pacing or Recording in the Later Years Unknown status NCT01423994 Phase 4
4 Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Unknown status NCT02495064 Phase 4 Mometasone Furoate Cream
5 Safety of Amiodarone and Ranolazine Together in Patients With Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
6 The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding Unknown status NCT02385422 Phase 4 Carvedilol;Propranolol
7 Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas Unknown status NCT01960569 Phase 4 active product ( Thrombexx) assigned to arm 1
8 Feasibility Study of the Intensive Systolic Blood Pressure Control Unknown status NCT02817503 Phase 4 Standard BP control;Moderate BP control;Intensive BP control
9 A Randomized Trial of Angiotensin Receptor bLocker,Fimasartan, in Aortic Stenosis (ALFA Trial) Unknown status NCT01589380 Phase 4 Fimasartan;Placebo
10 Aortic Stenosis and PhosphodiEsterase Type 5 iNhibition (ASPEN): A Pilot Study Unknown status NCT01275339 Phase 4 Tadalafil;Placebo
11 ISSUE3: International Study on Syncope of Uncertain Etiology 3 Completed NCT00359203 Phase 4
12 Clinical Trial for the Prevention of Vasovagal Syncope Completed NCT00118482 Phase 4 fludrocortisone acetate
13 Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance Completed NCT00060866 Phase 4 Propranolol
14 ELIAS: Early Loop-Recorder in Suspected Arrhythmogenic Syncope Completed NCT00170261 Phase 4
15 Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01518946 Phase 4 Midodrine HCl;Placebo
16 Comparision of Blood Pressure Variability Between Amlodipine and Losartan Completed NCT01964079 Phase 4 Amlodipine;Losartan
17 Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263) Completed NCT01131182 Phase 4 Sitagliptin phosphate;Comparator: Sulfonylurea;Metformin
18 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
19 Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis. Completed NCT01323673 Phase 4 clobetasol propionate 0.05%;Vehicle / Placebo
20 Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries Completed NCT02132247 Phase 4 Diclofenac hydroxyethylpyrrolidine
21 A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
22 Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension Completed NCT01515865 Phase 4 Midodrine HCl;Placebo
23 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
24 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
25 Postoperative Pain in Single-visit and Multiple-visit Retreatment Cases Completed NCT03042377 Phase 4 Multiple-Visit-"Calcium Hydroxide";Multiple-Visit-"Corticosteroid Paste";Multiple-Visit-"Antibiotic Paste"
26 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
27 Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia Completed NCT03109314 Phase 4 Donepezil
28 Optimal Balloon Catheter Placement During Sonohysterography Completed NCT01936116 Phase 4
29 A Study for Patients With Neurogenic Orthostatic Hypotension Completed NCT00046475 Phase 4 Midodrine Hydrochloride
30 Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin Completed NCT00373360 Phase 4 treprostinil sodium
31 Circadian Ocular Perfusion Pressure and Ocular Blood Flow Completed NCT00800540 Phase 4 Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension;Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution
32 Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION) Completed NCT02191137 Phase 4 Riociguat (Adempas, BAY63-2521)
33 Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis Completed NCT00936065 Phase 4 Etanercept;Etanercept + Acitretin;Acitretin
34 Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
35 An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation Completed NCT01644396 Phase 4
36 Epoprostenol for Injection in Pulmonary Arterial Hypertension Completed NCT01105091 Phase 4 ACT-385781A (Actelion Epoprostenol);Flolan®
37 STUDY TO ASSESS THE LONG-TERM SAFETY OF EXTINA (KETOCONAZOLE) FOAM, 2% Completed NCT00703846 Phase 4 Ketoconazole
38 PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial Completed NCT02382016 Phase 4 Macitentan
39 Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH) Completed NCT01462565 Phase 4 current marketed FLOLAN (epoprostenol sodium);new thermo stable formulation of epoprostenol sodium
40 A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic Disorder Completed NCT00677352 Phase 4 sertraline;Paroxetine
41 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
42 DUAC® Early Onset Efficacy Study in Japanese Subjects Completed NCT02557399 Phase 4 Duac® fixed dose combination gel;ADA 0.1% gel;CLDM 1% gel
43 Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
44 Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis Completed NCT00581100 Phase 4 etanercept
45 Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects Recruiting NCT02123056 Phase 4 Metoprolol;Matching Placebo
46 Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension Recruiting NCT02586623 Phase 4 Droxidopa capsules;Placebo capsules
47 Beta Blocker Interruption After Uncomplicated Myocardial Infarction Recruiting NCT03498066 Phase 4 Beta-blockers withdrawal;Continuation of the Betablockers (βB) treatment
48 CRyoAblation vs AntiaRrhythmic Drugs for Persistent Atrial Fibrillation Trial Recruiting NCT03716934 Phase 4 Antiarrhythmic drug
49 Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Recruiting NCT03278509 Phase 4 Metoprolol Succinate;Bisoprolol
50 The Effect of Antihypertensive Medication Timing on Morbidity and Mortality Recruiting NCT02990663 Phase 4

Search NIH Clinical Center for Fainting

Genetic Tests for Fainting

Anatomical Context for Fainting

MalaCards organs/tissues related to Fainting:

41
Brain, Skin, Heart, Testes, Bone, Whole Blood, Spinal Cord

Publications for Fainting

Articles related to Fainting:

(show top 50) (show all 197)
# Title Authors Year
1
Putting the Spirit into Culturally Responsive Public Health: Explaining Mass Fainting in Cambodia. ( 29956053 )
2018
2
Fear of blood, injections and fainting as barriers to blood donation in Brazil. ( 30485453 )
2018
3
Case report: fainting during acupuncture stimulation at acupuncture point LI4. ( 28274225 )
2017
4
Fainting Fanconi syndrome clarified by proxy: a case report. ( 28693455 )
2017
5
Sympathetic and parasympathetic cardiac responses to phobia-relevant and disgust-specific emotion provocation in blood-injection-injury phobia with and without fainting history. ( 28667690 )
2017
6
Fainting episode in a pacemaker dependent patient with two implanted devices. Too much of a good thing! ( 28476432 )
2017
7
Comparison of Specific Fainting Characteristics Between Youth With Tilt-Induced Psychogenic Nonsyncopal Collapse Versus Reflex Syncope. ( 28236458 )
2017
8
Mass fainting in garment factories in Cambodia. ( 28398195 )
2017
9
Fainting: What You Should Know. ( 28290650 )
2017
10
Clinical Pearls - how my patients taught me: The fainting lark symptom. ( 27822381 )
2016
11
An Experimental Model of Vasovagal Syncope Induces Cerebral Hypoperfusion and Fainting-Like Behavior in Awake Rats. ( 27658057 )
2016
12
Syncope (Fainting). ( 27142609 )
2016
13
Fainting Starting Parenteral Nutrition. ( 25853719 )
2015
14
Fifteen-minute consultation on limiting investigations in the fainting child. ( 26201347 )
2015
15
Fainting After Chest Pain. ( 27122877 )
2015
16
Alteration in cardiovascular and postural control relationship in non-fainting elderly individuals. ( 25570750 )
2014
17
Purinergic profile of fainting divers is different from patients with vasovagal syncope. ( 24798778 )
2014
18
Fainting as an unusual presentation of a large inferior vena cava leiomyosarcoma. ( 24837084 )
2014
19
Role of sympathetic nerve activity in the process of fainting. ( 25309444 )
2014
20
Fainting (vasovagal syncope): case reports. ( 25198333 )
2014
21
A mobile system for real-time context-aware monitoring of patients' health and fainting. ( 25946886 )
2014
22
Giving blood donors something to drink before donation can prevent fainting symptoms: is there a physiological or psychological reason? ( 25130724 )
2014
23
57-year-old man with flushing and fainting. ( 23639502 )
2013
24
Small left atrial volume is an independent predictor for fainting during head-up tilt test: the impact of intracardiac volume reserve in vasovagal syncope. ( 22000265 )
2013
25
External pneumatic compression device prevents fainting in standing weight-bearing MRI: a cohort study. ( 23857423 )
2013
26
Malignant cardioinhibitory vasovagal syncope - an uncommon cardiovascular complication of Roux-en-Y gastric bypass surgery: the fainting syndrome! ( 23063207 )
2013
27
A 40-year-old man with recurrent fainting, hypotension, lower limb edema and oliguria with body weight gain and secondary erythrocytosis. ( 21948352 )
2012
28
A pacemaker to prevent fainting. If your heart rate slows, a device can stop you from dropping. ( 23101130 )
2012
29
What's at the heart of fainting? Most fainting is not related to abnormal heart rhythms. ( 22872881 )
2012
30
Does disgust increase parasympathetic activation in individuals with a history of fainting? A psychophysiological analysis of disgust stimuli with and without blood-injection-injury association. ( 23023164 )
2012
31
The relation between disgust-sensitivity, blood-injection-injury fears and vasovagal symptoms in blood donors: disgust sensitivity cannot explain fainting or blood donation-related symptoms. ( 21906532 )
2012
32
Fainting attacks in children. ( 21695380 )
2012
33
Fainting, swooning, and syncope. ( 22132356 )
2011
34
Factors associated with fainting: before, during and after whole blood donation. ( 21535440 )
2011
35
Physiologic strategies to prevent fainting responses during or after whole blood donation. ( 21645008 )
2011
36
Episode of fainting and tetany after an evaluation technique of the upper cervical region: a case report. ( 20724209 )
2011
37
To avoid fainting: cross the legs and not the fingers. ( 20106794 )
2010
38
A 46-year-old woman with chin pain and a fainting spell. ( 20391493 )
2010
39
Correlations between urinary excretion of catecholamines and electrocardiographic parameters of vagal hyperreactivity in infants with fainting spells. Implication of sympathetic hypotonia? ( 21074121 )
2010
40
A 37-year-old man with recurrent fainting: a short communication. ( 20348158 )
2010
41
Fainting with HIV. ( 20800149 )
2010
42
Clinical reasoning: a teenage girl with excessive daytime sleepiness, "fainting spells," and dream mentations. ( 20498429 )
2010
43
Persistent fainting after implantation of a "curative" pacemaker. ( 19118314 )
2009
44
Increased phase synchronization and decreased cerebral autoregulation during fainting in the young. ( 19820196 )
2009
45
Low creatine kinase is associated with a high population incidence of fainting. ( 19468786 )
2009
46
Physiological correlates of applied tension may contribute to reduced fainting during medical procedures. ( 19730965 )
2009
47
Diagnostic tests for fainting found expensive, ineffective. The cheapest test for syncope--a postural blood pressure recording--may yield the most answers. ( 20120509 )
2009
48
Fainting, emancipation and the 'weak and sensitive' sex. ( 19567743 )
2009
49
Fainting and hemolysis during blood sampling in youngsters: prevalence study. ( 17331515 )
2008
50
Behavioral avoidance and self-reported fainting symptoms in blood/injury fearful individuals: an experimental test of disgust domain specificity. ( 17920808 )
2008

Variations for Fainting

Expression for Fainting

Search GEO for disease gene expression data for Fainting.

Pathways for Fainting

GO Terms for Fainting

Cellular components related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.62 F8 VWF

Biological processes related to Fainting according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood coagulation GO:0007596 9.32 F8 VWF
2 platelet degranulation GO:0002576 9.26 F8 VWF
3 platelet activation GO:0030168 9.16 F8 VWF
4 hemostasis GO:0007599 8.96 F8 VWF
5 blood coagulation, intrinsic pathway GO:0007597 8.62 F8 VWF

Sources for Fainting

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....